Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-01802 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Sapna P Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Cancer Center, Aurora, CO. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Immunotherapy, Ipilimumab, Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Colorado Cancer Center, Aurora, CO.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Sapna P Patel, Rahul A Sheth
Zitieren
APA
Patel, S. P., Sheth, R. A., Davis, C., & Medina, T. (2025). Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01802
Vancouver
Patel SP, Sheth RA, Davis C, Medina T. Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01802
BibTeX
@article{Patel2025,
author = {Patel, Sapna P and Sheth, Rahul A and Davis, Christina and Medina, Theresa},
title = {Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-01802}
}
EUVIMED